Hepatitis B cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Joao Silva (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hepatitis B}} | {{Hepatitis B}} | ||
{{CMG}}; {{AE}} {{JS}} | |||
==Overview== | |||
Attending to the inceased risk of developing complications, such as cirrhosis or [[hepatocellular carcinoma]], in infants and young children who are infected with the HBV and the benefits of vaccination and postexposure prophylaxis, the prevention and treatment of hepatitis B are considered cost-effective. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Hepatitis|B]] | [[Category:Hepatitis|B]] | ||
[[Category:Viruses]] | [[Category:Viruses]] | ||
| Line 14: | Line 16: | ||
[[Category:Mature chapter]] | [[Category:Mature chapter]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Revision as of 19:02, 30 July 2014
|
Hepatitis B |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hepatitis B cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Hepatitis B cost-effectiveness of therapy |
|
Risk calculators and risk factors for Hepatitis B cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
Attending to the inceased risk of developing complications, such as cirrhosis or hepatocellular carcinoma, in infants and young children who are infected with the HBV and the benefits of vaccination and postexposure prophylaxis, the prevention and treatment of hepatitis B are considered cost-effective.